Manipur, Jan. 7 -- As the first groups to receive the shots are from the health care providers, if there are side effects, the question is who will care for those who are ill?

At long last, after a few countries have issued Emergency Use Authorisation (EUA) of vaccines for COVID-19, India also issued EUA for two vaccines Covishield developed by Oxford-AstraZeneca and manufactured by Serum Institute of India (SII), which was the frontrunner and Covaxin developed and manufactured by Bharat Biotech. The moment EUA was issued, there was grumbling that the EUA for the latter was issued without undergoing Phase III trial and this forced a clarification that Covaxin will be the standby and all those who receive the shots of this vaccine will be...